Philips statement on recent FDA safety notification related to DreamStation 2

[ad_1] Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced…

Philips provides update on Respironics recall

[ad_1] Together with five independent, certified testing laboratories, Philips Respironics conducted extensive testing. Based on the results to date, Philips Respironics concluded that use of its sleep therapy devices are…

Philips response to recent media articles related to Philips Respironics’ voluntary recall notification/field safety notice

[ad_1] Philips’ priority is patient safety and quality. We understand how important Philips Respironics’ sleep therapy devices and ventilators are to patients that use them. Philips regrets any distress and…

Philips reaches resolution of US economic loss litigation

[ad_1] Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced today that the company and certain of its US subsidiaries, including Philips Respironics, have reached an agreement to resolve…